中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
1期
111-111,113
,共2页
前列腺增生%特拉唑嗪%爱普列特
前列腺增生%特拉唑嗪%愛普列特
전렬선증생%특랍서진%애보렬특
Benign Prostatic hyperplasia%terazosin%epristeride
目的：考察α1受体阻滞剂和5α还原酶抑制剂联用在前列腺增生中的治疗效果及应用前景。方法：选取在我院呼吸科2010年5月至2011年6月(在我院)收治前列腺增生80例,随机分为特拉唑嗪对照组和特拉唑嗪+爱普列特实验组,两组患者均接受相应药物16周,考察实验前后IPSS、QOL、MFR、RU、PV,比较两组患者治疗率。结果：两组患者均能一定程度改善前列腺增生症状,但是实验组各指标均优于对照组(P<0.05),治疗组MRF和IPSS改善率分别为77%和44%,对照组分别为44%和21%,两者均有统计学差异(P<0.01)。结论：α1受体阻滞剂和5α还原酶抑制剂联合使用对前列腺增生的治疗效果优于单用α1受体阻滞剂。
目的：攷察α1受體阻滯劑和5α還原酶抑製劑聯用在前列腺增生中的治療效果及應用前景。方法：選取在我院呼吸科2010年5月至2011年6月(在我院)收治前列腺增生80例,隨機分為特拉唑嗪對照組和特拉唑嗪+愛普列特實驗組,兩組患者均接受相應藥物16週,攷察實驗前後IPSS、QOL、MFR、RU、PV,比較兩組患者治療率。結果：兩組患者均能一定程度改善前列腺增生癥狀,但是實驗組各指標均優于對照組(P<0.05),治療組MRF和IPSS改善率分彆為77%和44%,對照組分彆為44%和21%,兩者均有統計學差異(P<0.01)。結論：α1受體阻滯劑和5α還原酶抑製劑聯閤使用對前列腺增生的治療效果優于單用α1受體阻滯劑。
목적：고찰α1수체조체제화5α환원매억제제련용재전렬선증생중적치료효과급응용전경。방법：선취재아원호흡과2010년5월지2011년6월(재아원)수치전렬선증생80례,수궤분위특랍서진대조조화특랍서진+애보렬특실험조,량조환자균접수상응약물16주,고찰실험전후IPSS、QOL、MFR、RU、PV,비교량조환자치료솔。결과：량조환자균능일정정도개선전렬선증생증상,단시실험조각지표균우우대조조(P<0.05),치료조MRF화IPSS개선솔분별위77%화44%,대조조분별위44%화21%,량자균유통계학차이(P<0.01)。결론：α1수체조체제화5α환원매억제제연합사용대전렬선증생적치료효과우우단용α1수체조체제。
Objective:To investigated alpha 1 receptor blockers and 5 alpha reductase inhibitors combination treat effect in hyperplasia of prostate. Methods:Selected prostate hyperplasia 80 patients in our hospital from May 2010 to June 2011,the patients were randomly divided into the terazosin control group and of (terazosin the+epristeride) experimental group, two groups patients al received drugs for 16 weeks, visits before and after the experiment,recorded IPSS, QOL, MFR, RU and PV in two groups.Results:Both groups al could improve the symptoms of prostatic hyperplasia, but the experimental group were bet er than the control group (P<0.05), the treatment group MRF and IPSS improvement rates were 77%and 44%, in the control group were 44%and 21%, both of which were significantly different (P<0.01).Conclusion:Alpha 1 reductase blockers and 5-alpha reductase inhibitor combined with the use of bet er treatment effect on benign prostate hyperplasia with alpha 1 reductase blockers.
